Alcon Research

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alcon Research sits in the top decile of US sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count).

275 total trials 5 currently recruiting 248 completed later-stage tilt top decile by trial count

Alcon Research: 275 sponsored US clinical trials, 5 recruiting.

Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.

Top-decile sponsor footprint

Alcon Research ranks in the top decile of sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

248 of 266 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

275 total, page 3 of 6

COMPLETED NA

DD T2 Daily Disposable Registration Trial

NCT03305770

TERMINATED NA

Post Approval Study of the CyPass System

NCT03273907

COMPLETED NA

A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)

NCT03274986

COMPLETED NA

Clinical Investigation of the Clareon® Intraocular Lens (IOL)

NCT03170154

COMPLETED NA

Assessing Fitting Guides in Alcon Multifocal Contact Lenses

NCT03118934

COMPLETED NA

Clinical Performance of a Silicone Hydrogel for Daily Disposable Wear

NCT03095027

COMPLETED NA

Early Feasibility Study of UV-Femtosecond Laser Assisted Lenticular Extraction

NCT03021707

COMPLETED NA

Clinical Biocompatibility Evaluation of Contact Lens Coatings

NCT03034928

TERMINATED Phase 4

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871

COMPLETED NA

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

NCT02700984

COMPLETED Phase 1

Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)

NCT02539654

COMPLETED NA

Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study

NCT02575911

COMPLETED Phase 4

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508

TERMINATED Phase 1

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

NCT02398500

COMPLETED NA

Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes

NCT02477605

COMPLETED Phase 3

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

NCT02307682

COMPLETED NA

Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems

NCT01699750

COMPLETED Phase 4

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

NCT01697969

COMPLETED NA

Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses

NCT01561560

COMPLETED

Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9

NCT01601665

COMPLETED NA

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

NCT01497067

COMPLETED Phase 1

Safety and Efficacy of AL-53817 Nasal Spray Solution

NCT01454505

COMPLETED Phase 2

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

NCT01157065

COMPLETED NA

Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS)

NCT01476722

COMPLETED Phase 2

ESBA105 in Patients With Severe Dry Eye

NCT01338610

COMPLETED Phase 4

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951

COMPLETED NA

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

NCT01368198

COMPLETED Phase 2

Nepafenac 0.3% Two Study

NCT01318499

COMPLETED Phase 4

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569

COMPLETED NA

Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers

NCT01484938

COMPLETED Phase 2

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223

COMPLETED Phase 4

Assessment of Alcon's Ocular Image Quantification System

NCT01282138

COMPLETED NA

Effect of FID 114675A on Lens Wettability

NCT01342107

COMPLETED Phase 3

Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

NCT01201798

COMPLETED NA

Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers

NCT01211535

COMPLETED Phase 3

Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

NCT01124045

COMPLETED NA

Alcon Multi-Purpose Disinfecting Solution Versus Renu Fresh Multi-Purpose Solution in Symptomatic Contact Lens Wearers

NCT01187355

COMPLETED Phase 4

A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs)

NCT01166971

COMPLETED NA

An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation Following Intraocular Lens (IOL) Implantation

NCT01190631

COMPLETED Phase 3

Confirmatory Study Nepafenac 0.3%

NCT01109173

TERMINATED

Natural History Study of Incidence of Otorrhea Following Tympanostomy Tube Insertion in Children 6 Months to 12 Years

NCT01111877

COMPLETED Phase 2

Travoprost Five Day Posology Study

NCT01114893

COMPLETED Phase 3

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244

COMPLETED NA

A Comparative Pilot Study Of High-Order Aberrations With Aspheric IOL Models SN60WF and ZCB00

NCT01105585

COMPLETED Phase 4

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287

COMPLETED NA

Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining

NCT01100424

COMPLETED Phase 4

Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets

NCT01057966

TERMINATED Phase 3

Safety and Efficacy of Moxidex Otic

NCT01071902

COMPLETED NA

Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness

NCT01066988

COMPLETED NA

A Comparison of Corneal Aberrations in Subjects With Contralateral AcrySof IQ Toric Intraocular Lens (IOL) and AcrySof IQ IOL With Limbal Relaxing Incision (LRI)

NCT01045733

← Previous Page 3 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 23
Phase 3 47
Phase 4 40

Where Alcon Research enrollment is open (later-stage tilt)

5 recruiting of 275 indexed (2% open); 248 completed (90%).

Phase mix: 87 late (III/IV) vs 28 early (I/II) (later-stage heavy).

Top condition: Cataract (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alcon Research: open-pipeline peers nationwide

Peers matched on 275 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15%20%25% Total trials Recruiting share Alcon ResearchBoston Scientific CorporationRegeneron PharmaceuticalsSWOG Cancer Research NetworkNovartisLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLexicon PharmaceuticalsSociété des Produits Nestlé (SPN)Eisai
Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 275 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

What to do with this Alcon Research page

275 registered trials is a research-attention snapshot, not an endorsement of Alcon Research or any single study.

  • 5 of Alcon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cataract is the condition Alcon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alcon Research pipeline card: 275 registered trials from official public datasets.Report a data error.